Development Pipeline

Development Pipeline

Focused on rare diseases, we are developing new therapies to address unmet medical needs.Learn more about our latest pipeline progress below.

(As of July 30, 2026)

Development pipeline table summarizing code/product name, planned indication, development stage, and notes. It shows the progress of JR-141, JR-142, JR-401G, JR-171, JR-441, JR-446, JR-471, JR-479, and Givinostat from preclinical development to approval. JR-141 is approved in Japan and in global Phase 3; JR-142 and JR-401G are in Japan Phase 3; JR-171 is in global Phase 1/2; JR-441 is in Germany Phase 1/2 and Japan Phase 1; JR-446 is in Japan Phase 1/2; JR-471 and JR-479 are in preclinical development; and Givinostat for Duchenne muscular dystrophy is partnered with Italfarmaco S.p.A. and approved in the US, the EU and other countries.